Product Highlight - Forxiga

Forxiga provides early cardiorenal benefits beyond HbA1c in a broad type 2 diabetes patient population
• Superior HbA1c reduction vs DPP4i^1-2
• Well-established safety profile with no imbalance of AEs* vs placebo^3-5
• Early cardiorenal benefits beyond HbA1C in a broad T2DM patients population⁶

*AEs included are amputations, fractures, bladder cancer or Fournier’s gangrene
Disclaimer: Forxiga is not indicated to reduce the risk of CV events, CV death or hospitalisation for heart failure or for the treatment of CKD

References:
1. Bailey CJ, Gross JL, Pieters A, Bastein A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo- controlled trial. Lancet. 2010;375(9733):2223-2233.                 
2. Rosenstock J, Mathieu C, Chen H, et al. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin. Arch Endocrinol Metab. 2018;62(4):424-430
3. Data on file. Atlas Approval ID: 801,453.011. AstraZeneca Pharmaceuticals Ltd.
4. FORXIGA Malaysia Prescribing Information (Doc ID-002317198, Version 13.0). April 2018
5. Jabbour S, Seufert J, Scheen A, Karup C, Langkilde AM. The incidence of amputation in the dapagliflozin clinical trial program. Endoc Pract. 2017;23(1):46A.
6. Wiviott SD, Raz I, Bonaca MP, et al. Dapaglifozin and cardiovascular outcomes in type-2 diabetes. N Engl J Med. 2018. doi: 10.1056/NEJMoa1812389

Further information is available in section 11b and in mims.com.
Full prescribing information is available upon request.